Balanced Portfolio, Strategy Update

Strategy Update: Switch 2% of Neuren Pharma (NEU) to Telix Phama(TLX)

Switching from Neuren Pharma (NEU) to Telix Pharma (TLX) in our balanced portfolio, capitalizing on Telix’s innovative cancer treatment advancements and market potential.